PATENT CLAIM ANALYSIS

Application Number: 16190792
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-03
Patent Classification: ["514", "121000"]

Abstract:
Methods and compounds are disclosed for treating inflammatory bowel disease (IBD) by using Prostate Specific Membrane Antigen (PSMA) inhibitors.

Claim (Index 13):
The method of  claim 11 , wherein the Tris-POC-2-PMPA is administered to the subject orally.

Metadata:
- Claim Count in Document: 41.0
- Percentile: 98.0
- Lexical Diversity: 1.09091
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15502009', '15968074', '15502105', '10412151', '11851669']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7471307674680028
- 35 USC 102 Novelty (BERT): 0.597419480411151
- Combined Prediction Score: 0.7321596387623176
- Mean Citation Score: 322.789752
- Max Citation Score: 519.625
- Similarity Product: 430.06995965540415

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test